Trial Profile
Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients (ISAV).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms ISAV
- 09 Jun 2020 Results assessing final results of ISAV after a in non-relapsed patients median follow-up of 49 months published in the Blood
- 28 Nov 2019 Status changed from active, no longer recruiting to completed.
- 13 Nov 2019 Results assessing the role of digital PCR published in the Blood